Belite Bio, Inc (NASDAQ:BLTE) Receives $44.83 Average Price Target from Brokerages
Shares of Belite Bio, Inc (NASDAQ:BLTE – Get Free Report) have been given an average recommendation of “Buy” by the seven analysts that are covering the company, Marketbeat reports. Seven research analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have covered the stock in the last […]